Sponsorsview all sponsors
MSHO continuously contacts legislators, provides comments to policy makers and collaborates with payers on issues of concern to those delivering care to cancer patients.
It is important that our members are aware of meetings, web casts, and other educational opportunities specifically designed to address the complexities of cancer care.
REVLIMID (lenalidomide) is NOW INDICATED in relapsed or refractory mantle cell lymphoma (MCL)
REVLIMID (lenlidomide) is now indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. READ MORE